Investigation of Programmed Cell Death-۱ (PD-۱) Gene Variations at Positions PD۱.۳ and PD۱.۵ in Iranian Patients with Non-small Cell Lung Cancer
محل انتشار: مجله سرطان خاورمیانه، دوره: 9، شماره: 1
سال انتشار: 1397
نوع سند: مقاله ژورنالی
زبان: انگلیسی
مشاهده: 74
فایل این مقاله در 5 صفحه با فرمت PDF قابل دریافت می باشد
- صدور گواهی نمایه سازی
- من نویسنده این مقاله هستم
استخراج به نرم افزارهای پژوهشی:
شناسه ملی سند علمی:
JR_MISJ-9-1_003
تاریخ نمایه سازی: 25 آبان 1402
چکیده مقاله:
Background: Tumor cells express PD-۱ ligands to bind PD-۱ on immune cells and escape immune responses. In the present study, we aimed to investigate whether single nucleotide polymorphisms at positions PD۱.۳ (+۷۱۴۶, rs۱۱۵۶۸۸۲۱) G/A, and PD۱.۵ (+۷۷۸۵ C/T, rs۲۲۲۷۹۸۱) may be considered risk factors for susceptibility to nonsmall cell lung cancer in the Iranian population. Methods: This study enrolled ۲۰۶ histopathologically confirmed lung cancer patients and ۱۷۳ age/sex matched healthy controls. We performed PCR-RFLP to determine the genotypes of the extracted genomic DNA.Results: The frequencies of PD۱.۳ GG, GA and AA genotypes were ۱۷۱ (۸۳%), ۳۱ (۱۵%) and ۴ (۱.۹%) out of ۲۰۶ patients, and ۱۴۴ (۸۳.۲%), ۲۶ (۱۵%), and ۳ (۱.۷%) out of ۱۷۳ controls, respectively. The frequencies of PD۱.۵ CC, CT and TT genotypes were ۷۸ (۳۷.۹%), ۱۰۰ (۴۸.۵%), and ۲۸ (۱۳.۶%) in patients, and ۶۰ (۳۴.۷%), ۸۹ (۵۱.۴%), and ۲۴ (۱۳.۹%) in controls. There were no significant differences in genotype analysis between patients and controls at positions PD۱.۳ (P=۰.۹۸) or PD۱.۵ (P=۰.۸۰). No significant differences existed in the frequencies of alleles and haplotypes between the two groups (P>۰.۰۵).Conclusion: Our data have indicated no association between PD۱.۳ (+۷۱۴۶) G/A and PD۱.۵ (+۷۷۸۵) C/T with susceptibility to non-small cell lung cancer. Investigation of other PD۱ genetic variations and emerged haplotypes are required to completely define the role of PD۱ genetic variations in susceptibility to lung cancer.
نویسندگان
Zahra Piredelkhosh
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Tohid Kazemi
Immunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran
Mohammad Reza Haghshenas
Cancer Immunology Group, Shiraz Institute for Cancer Research, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Mohammad Ali Ghayumi
Department of Internal Medicine, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran
Nasrollah Erfani
Department of Internal Medicine, Faghihi Hospital, Shiraz University of Medical Sciences, Shiraz, Iran